• Gleneagles Medical Centre, 6 Napier Road, #08-08, S258499

Schedule an Appointment

Please fill in the form and our staff contact you to schedule an appointment as soon as we can.


Another double-first at the VEC: MagicTouch & Nitides

Recently Dr Wong and Dr Tang had to redo a lower limb revascularization procedure that came from a public hospital for a non healing toe amputation wound. The arteries were heavily calcified and required balloon angioplasty and a stent. After ballooning the narrowings in the blood vessels they used a specialised balloon lined with a special drug called sirolimus to reduce the chance of renarrowing. This was the first time MagicTouch from Concept Medical has been used in private in Singapore along with a drug eluting sirolimus stent called Nitides.

Here are some key points about the MagicTouch balloon for peripheral artery disease:

  • The MagicTouch balloon is a sirolimus-coated balloon (SCB) used to treat peripheral arterial disease.

  • It has been demonstrated to achieve good short-term patency (12 months) without major adverse events or device-related shortcomings.

  • The MagicTouch balloon employs the use of phospholipid to achieve 100% sirolimus sub-micron particle coating on its balloon surfaces, allowing for controlled drug delivery into the arterial wall.

  • The balloon’s coating technology enables prolonged drug elution at therapeutic levels to minimise neointimal hyperplasia and restenosis.

  • Studies have shown high procedural success rates, low device-related adverse events, and low target lesion revascularization rates with the MagicTouch balloon.

The NiTides stent is a self-expanding, drug-eluting stent for treating peripheral artery disease lesions in superficial femoral arteries ¹. Here are some key points about the NiTides stent:

  • Received CE Mark approval in May 2021.

  • Elutes Amphilimus (sirolimus plus fatty acid) through abluminal reservoir technology

  • Polymer-free device with a nitinol body sealed by a bio-inducer surface.

  • High hemo and biocompatibility, potentially reducing thrombogenicity.

  • ILLUMINA study results at 2 years: 91.9% freedom from device-related major adverse events, 93.1% freedom from target lesion revascularization, and 83.4% primary patency rate.

  • Demonstrated long-term safety and efficacy performance.

Book your appointment online

Our simple to use, online appointment process makes it easy for you to book for any one of our services and doctors.

Related Posts

Erectile dysfunction (ED) affects the confidence and intimate relationships of men. This condition is the …

Leave a Reply

Your email address will not be published. Required fields are marked *